The prognostic impact of comorbidity, nutritional and performance status on patients with diffuse large B cell lymphoma

dc.authorid0000-0003-4766-1861
dc.contributor.authorSağlam, Buğra
dc.contributor.authorAlbayrak, M.
dc.contributor.authorYıldız, Abdulkerim
dc.contributor.authorTı?lıo?lu, P.
dc.contributor.authorTı?lıo?lu, M.
dc.contributor.authorAras, M. R.
dc.contributor.authorYılmaz, F.
dc.contributor.authorMaral, Senem
dc.contributor.authorÖztürk, H. B. A.
dc.date.accessioned2023-11-27T09:02:47Z
dc.date.available2023-11-27T09:02:47Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground: The aim of the study was to investigate the impact of nutritional status, comorbidity, and performance status on patients with diffuse large B-cell lymphoma (DLBCL). Methods: A retrospective study was conducted on 112 DLBCL patients who were diagnosed at our center between 2009 and 2018. Demographic and disease characteristics and laboratory test results were recorded. Assessments were made using the age-adjusted Charlson comorbidity index (CCI-A) for comorbidity, albumin level for nutritional status, and Eastern Cooperative Oncology Group (ECOG) score for performance status. Results: The mean age of the patients was found to be 62.63 ± 15.16 years. The ECOG score of 65 patients (69.1%) was in the range of 0-1. The mean follow-up time of the patients was determined to be 25.24 ± 25.11 months, and at the end of the follow-up period, 64 patients (57.1%) were survivors. The progression-free survival (PFS), overall survival (OS), and 5-year OS rates of those with CCI-A > 4 were found to be significantly lower than those with CCI-A score ?4 (P < 0.05). As a result of the Cox-Regression (Backward: LR method) analysis, ECOG and albumin levels were found to be independent risk factors for both OS and PFS (P < 0.05). Conclusion: This study demonstrated that CCI-A, ECOG, and nutritional status are independent prognostic markers for DLBCL patients. Initial evaluation of these patients should include all these parameters, which are easily available at the time of diagnosis.
dc.identifier.citationSağlam, B., Albayrak, M., Yıldız, A., Tı?lıo?lu, P., Tı?lıo?lu, M., Aras, M. R. ... Öztürk, H. B. A. (2023). The prognostic impact of comorbidity, nutritional and performance status on patients with diffuse large B cell lymphoma. Nigerian Journal of Clinical Practice, 26(10), 1512-1518. https://dx.doi.org/10.4103/njcp.njcp_175_23
dc.identifier.doi10.4103/njcp.njcp_175_23
dc.identifier.endpage1518
dc.identifier.issn1119-3077
dc.identifier.issn2229-7731
dc.identifier.issue10
dc.identifier.pmid37929528
dc.identifier.scopus2-s2.0-85176375622
dc.identifier.scopusqualityQ3
dc.identifier.startpage1512
dc.identifier.urihttps://dx.doi.org/10.4103/njcp.njcp_175_23
dc.identifier.urihttps://hdl.handle.net/20.500.12511/11878
dc.identifier.volume26
dc.identifier.wos001094966700015en_US
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorMaral, Senem
dc.language.isoen
dc.publisherWolters Kluwer Medknow Publications
dc.relation.ispartofNigerian Journal of Clinical Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAlbumin
dc.subjectCharlson Comorbidity
dc.subjectLymphoma
dc.subjectPerformance
dc.subjectPrognosis
dc.titleThe prognostic impact of comorbidity, nutritional and performance status on patients with diffuse large B cell lymphoma
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Maral-Senem-2023.pdf
Boyut:
676.08 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: